NOVO Novo Integrated Sciences, Inc. - 8-K

Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.

As
previously disclosed, on November 7, 2024, Robert Mattacchione resigned as Chief Executive Officer of  Novo
Integrated Sciences, Inc. (the “Company”), effective 90 days following the notification date (i.e. effective February 5,
2025). Also as previously disclosed, the effective date of Mr. Mattacchione’s resignation was subsequently extended to February
20, 2025, again to no later than March 7, 2025, again to no later than March 31, 2025, and again to no later than April 30, 2025.

Thereafter,
on April 30, 2025, the Company and Mr. Mattacchione agreed to extend the effective date of Mr. Mattacchione’s resignation to no
later than May 31, 2025, in order to provide the Company the necessary time to complete an efficient transition of the Chief Executive
Officer position.

Following
Mr. Mattacchione’s departure as Chief Executive Officer, Mr. Mattacchione intends to continue to serve as (i) the Company’s
Chairman of the Board of Directors (the “Board”), and (ii) Chairman of Novo Healthnet Limited, a wholly owned subsidiary
of the Company.  Mr. Mattacchione’s resignation
was not a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Also
on April 30, 2025, Michael Pope resigned as a member of the Board, effective May 1, 2025. Mr. Pope’s resignation was not
a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.